Global multi-societies endorsement of the MAFLD definition

Annals of Hepatology, Journal Year: 2024, Volume and Issue: 29(6), P. 101573 - 101573

Published: Oct. 31, 2024

Language: Английский

---

Dual‐aetiology MAFLD and metabolic dysfunction

Liver International, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 10, 2024

Language: Английский

---

Stigma Among Chinese Speaking Patients with Non-alcoholic Fatty Liver Disease and Their Providers

Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

---

Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association

Diabetes & Metabolism Journal, Journal Year: 2024, Volume and Issue: 48(6), P. 1015 - 1028

Published: Nov. 22, 2024

Since the role of liver in metabolic dysfunction, including type 2 diabetes mellitus, was demonstrated, studies on non-alcoholic fatty disease (NAFLD) and dysfunction-associated (MAFLD) have shown associations between other diseases. Unlike exclusionary diagnostic criteria NAFLD, MAFLD diagnosis is based presence dysregulation disease. Renaming NAFLD as also introduced simpler criteria. In 2023, a new nomenclature, steatotic (SLD), proposed. Similar to MAFLD, SLD hepatic steatosis with at least one cardiometabolic dysfunction. categorized into (MASLD), dysfunction alcohol-related/-associated disease, alcoholrelated specific etiology SLD, cryptogenic SLD. The term MASLD has been adopted by number leading national international societies due its concise criteria, exclusion concomitant diseases, lack stigmatizing terms. This article reviews clinical relevance, differences among from diabetologist's perspective provides rationale for adopting SLD/MASLD Fatty Liver Research Group Korean Diabetes Association.

Language: Английский

---

MAFLD or MASLD: Let the evidence decide again

Annals of Hepatology, Journal Year: 2024, Volume and Issue: 29(5), P. 101521 - 101521

Published: June 12, 2024

Language: Английский

---

NAFLD to MAFLD: collaboration, not confusion - rethinking the naming of fatty liver disease

Metabolism and Target Organ Damage, Journal Year: 2024, Volume and Issue: 4(4)

Published: Dec. 9, 2024

The recent shift from “non-alcoholic fatty liver disease” (NAFLD) and “metabolic associated (MAFLD) to dysfunction-associated steatotic (MASLD) has raised questions about its scientific basis impact on patient understanding. This renaming may create confusion rather than clarity. A collaborative approach involving healthcare professionals, researchers, patients establish terminology that balances accuracy with accessibility is needed. Effective disease naming should be accurate, unique, consistent, objective, accessible - qualities essential for clear communication in healthcare. Disease name more correctness because conventions public use, especially anything related health, must a matter of convenience, ethics, cultural social acceptance. Education straightforward take precedence over renaming, helping providers fully understand the complexities implications treatment. After all, health perspective, MAFLD advantages MASLD.

Language: Английский

---

Who better identifies significant liver fibrosis, MAFLD or MASLD, needs more rigorous, in-depth study

Hepatology International, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 24, 2024

Language: Английский

---

Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response

Metabolism and Target Organ Damage, Journal Year: 2024, Volume and Issue: 4(4)

Published: Nov. 13, 2024

The conceptual evolution of non-alcoholic fatty liver disease (NAFLD) to what, since 2023, is called metabolic dysfunction-associated steatotic (MASLD) not only represents a change in the classification and definition but also reflects broader understanding this heterogeneous condition, which still with many aspects refine. Although NAFLD can be interchanged high percentage new MASLD concept different aspects, has been proposed as relevant factor that influences response immunotherapeutic treatments management MASLD-related hepatocellular carcinoma (HCC), compared HCC other etiologies. This indicates etiology plays role prognosis, highlighting urgency evaluating treatment regimens for subgroup patients upcoming clinical trials. A better pathophysiology generates strategies aid its provide directly intervene carcinogenesis HCC.

Language: Английский

---

Bringing evidence to the MAFLD‐MASLD debate

Liver International, Journal Year: 2024, Volume and Issue: 44(7), P. 1740 - 1741

Published: May 27, 2024

Language: Английский

---